⌘K
Loading ticker…
As of 2026-08-24, Estrella Immunopharma, Inc. Common Stock (ESLA) has a 3-month relative strength percentile of 11 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 36. The current market Stance is 47.8 (Neutral). Sector: Healthcare, ranked 3 of 11. Average daily range 8.1%, relative volume 0.74×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
ESLA is in a stage 4 downtrend, week 8. Extended from base. VCP detected: inconclusive. Distance from 50d / 200d: -12.6% / -42.4%.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
Daily range, ATR, beta, and the math for a 1-ADR stop.
Diluted EPS, last 8 quarters. Loss makers are judged by progress toward breakeven.
YoY sales growth, last 8 quarters. Sales must back the earnings story.
Operating margin unavailable
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
ESLA is held by 2 ETFs as of Mar 2026. Top owner: VTI at 0.00% weight, $284K notional.
Held by 3 ETFs · $431K across latest filings · largest weight 0.00% (IWC).
Top 2 by value, from SEC N-PORT-P filings dated Mar 2026.
| ETF | Weight | Value | Δ |
|---|---|---|---|
| VTIVanguard Total Stock Market ETF | 0.00% | $284K | — |
| VXFVanguard Extended Market ETF | 0.00% | $121K | — |
As filed in N-PORT — quarterly holdings with up to ~60-day publication lag. Not live positioning.
Weak relative strength and quiet attention. Little to read here either way.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ESLA Jan avg: -13.27% median: -12.50% win: 33% σ: 14.57% n: 3 2023-10-03 → 2026-07-31 | ESLA Feb avg: -0.64% median: -1.91% win: 33% σ: 9.00% n: 3 2023-10-03 → 2026-07-31 | ESLA Mar avg: -0.52% median: -10.00% win: 33% σ: 19.19% n: 3 2023-10-03 → 2026-07-31 | ESLA Apr avg: 18.63% median: 16.50% win: 67% σ: 35.07% n: 3 2023-10-03 → 2026-07-31 | ESLA May avg: -16.63% median: -9.82% win: 0% σ: 14.74% n: 3 2023-10-03 → 2026-07-31 | ESLA Jun avg: 0.47% median: -4.59% win: 33% σ: 9.04% n: 3 2023-10-03 → 2026-07-31 | ESLA Jul avg: 1.57% median: -12.50% win: 33% σ: 41.79% n: 3 2023-10-03 → 2026-07-31 | ESLA Aug avg: 2.89% median: 2.89% win: 50% σ: 31.28% n: 2 2023-10-03 → 2026-07-31 (current) | ESLA Sep avg: 0.79% median: 0.79% win: 50% σ: 12.35% n: 2 2023-10-03 → 2026-07-31 | ESLA Oct avg: 8.50% median: -31.04% win: 33% σ: 89.01% n: 3 2023-10-03 → 2026-07-31 | ESLA Nov avg: 10.94% median: 3.75% win: 67% σ: 28.05% n: 3 2023-10-03 → 2026-07-31 | ESLA Dec avg: -17.82% median: -26.07% win: 33% σ: 20.70% n: 3 2023-10-03 → 2026-07-31 |